Other languages Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Real-time Estimate Cboe BZX Other stock markets 09:45:36 2024-04-19 am EDT			5-day change	1st Jan Change
4.65 ^USD	-0.21%		+0.50%	-30.71%

Apr. 09	Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	CI
Apr. 03	Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	Apr. 08
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	Apr. 03
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	Nov. 01
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	23-07-19
Top Midday Gainers	23-07-13
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Sector Update: Healthcare	22-12-16
Top Midday Decliners	22-12-16
Synaptogenix Shares Decline After Proposed Alzheimer's Disease Treatment Misses Primary Endpoint in Phase 2 Study	22-12-16
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease	22-12-16
Synaptogenix Announces $15 Million Private Placement	22-11-18
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05
Synaptogenix Doses First Patient in Alzheimer's Disease Dose Optimization Clinical Trial; Shares Rise	22-07-20
Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data	22-07-20
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13
Synaptogenix Completes Patient Enrollment in Phase 2b Trial of Drug Candidate for Alzheimer's Disease	22-04-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Other languages

Filters